Abstract
15 patients with myeloproliferative diseases and thrombocythaemia (7 Polycythaemia vera, 5 essential thrombocythaemia, 3 chronic myelogenous leukaemia) were assigned to a therapy with recombinant interferon (recombinant IFN-alpha-2C) in a prospective, controlled trial. Under therapy all patients showed a significant decrease in thrombocyte values. 51% of the patients revealed thrombocyte values within the normal range after 3 months of IFN therapy. Noted side effects of IFN therapy were dose-dependent and clinically well tolerated by the patients.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Aged
-
Clinical Trials as Topic
-
Drug Administration Schedule
-
Erythrocyte Count / drug effects
-
Female
-
Humans
-
Interferon Type I / therapeutic use*
-
Leukemia, Myeloid / drug therapy
-
Leukocyte Count / drug effects
-
Male
-
Middle Aged
-
Myeloproliferative Disorders / drug therapy*
-
Platelet Count / drug effects
-
Polycythemia Vera / drug therapy
-
Prospective Studies
-
Recombinant Proteins / therapeutic use*
-
Thrombocythemia, Essential / drug therapy
-
Thrombocytosis / drug therapy*
Substances
-
Interferon Type I
-
Recombinant Proteins